TrialJournal of the European Academy of Dermatology and Venereology : JEADV2025

Efficacy and safety of tozorakimab in moderate-to-severe atopic dermatitis: A Phase 2a randomized controlled trial (FRONTIER-2).

J I Silverberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.